Trenton T. Ross - Concepedia

Author

Trenton T. Ross

Also Known As

Amit S. Kalgutkar, Euan James McLeod, Paul Hockings, Trenton Ross, Trenton T Ross, Trenton T. Ross, Trenton Thomas Ross, Trenton Thomas Ross

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)

About

Trenton T. Ross is an author at Pfizer (United States) specializing in medicine, pharmacology, and liver physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	405
2	Health Sciences	4	4	284
3	Biochemistry	3	3	111
4	Natural Sciences	2	2	74
5	Biomedical Engineering	1	1	14

Trenton T. Ross

Publications

808

Citations

H-Index

Page 1

	Year	Citations
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials Roberto A. Calle, Neeta B. Amin, Santos Carvajal‐Gonzalez, Nature Medicine ObesityMetabolic SyndromeDgat2 InhibitorHepatologyAcc Inhibitor	2021	207
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD) Michèle Vacca, Ioannis Kamzolas, Lea Mørch Harder, Nature Metabolism	2024	183
Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems Trenton T. Ross, Collin Crowley, Kenneth L. Kelly, Cellular and Molecular Gastroenterology and Hepatology	2020	89
Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction Jemy A. Gutierrez, Wei Liu, Sylvie Perez, Molecular Metabolism	2021	80
Discovery of Fragment-Derived Small Molecules for in Vivo Inhibition of Ketohexokinase (KHK) Kim Huard, Kay Ahn, Paul A. Amor, Journal of Medicinal Chemistry Metabolic SyndromeMedicinal ChemistryVivo InhibitionDrug TargetBiochemistry	2017	49
De novo lipogenesis is essential for platelet production in humans Kenneth L. Kelly, William J. Reagan, Gabriele E. Sonnenberg, Nature Metabolism ThrombopoiesisThrombosisDevelopmental BiologyBlood PlateletHematology	2020	47
The Hepatoselective Glucokinase Activator PF-04991532 Ameliorates Hyperglycemia without Causing Hepatic Steatosis in Diabetic Rats Derek M. Erion, Amanda L. Lapworth, Paul A. Amor, PLoS ONE GlycobiologyGlucose HomeostasisFatty Liver DiseaseInsulin SignalingOxidative Stress	2014	37
The combination of exercise training and sodium-glucose cotransporter-2 inhibition improves glucose tolerance and exercise capacity in a rodent model of type 2 diabetes Melissa A. Linden, Trenton T. Ross, David A. Beebe, Metabolism Metabolic SyndromeGlucose TolerancePhysical ActivityKinesiologyDiabetes Management	2019	26
Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis Kentaro Futatsugi, Shawn Cabral, Daniel W. Kung, Journal of Medicinal Chemistry Liver FibrosisPathologyPharmacotherapyDiacylglycerol Acyltransferase 2Fatty Liver Disease	2022	25
Hepatic Activin E mediates liver-adipose inter-organ communication, suppressing adipose lipolysis in response to elevated serum fatty acids John D Griffin, Joanne Buxton, Jeffrey A. Culver, Molecular Metabolism	2023	24

Page 1